GlassScriptPhysician profile
Himanshu Desai
NPI 1013153014
$174,403.72
in general payments reported to CMS, 2019-2025
38 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,224 · 2020: $7,296 · 2021: $36K · 2022: $40K · 2023: $36K · 2024: $23K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $5,052 · Food and Beverage: $1,952 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,184.25 |
| Travel and Lodging | $5,051.99 |
| Food and Beverage | $1,951.52 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $95,362.58 | 2019-2023 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $52,209.61 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Mylan Specialty L.P. | $23,367.48 | 2019-2024 | Yupelri, Yupelri |
| Grifols USA, LLC | $427.54 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.63 | 2019-2022 | |
| Genzyme Corporation | $328.97 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $261.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $180.99 | 2022-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $175.24 | 2019-2022 | |
| Genentech USA, INC. | $141.36 | 2019-2020 | |
| Insmed, INC. | $126.09 | 2019 | |
| Abbvie INC. | $119.74 | 2021-2022 | |
| Pfizer INC. | $117.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $116.03 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himanshu Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.